Eurocine Vaccines AB (publ) engages in the development of vaccines in Sweden. The company is developing Herpes Simplex Virus type 2 and Chlamydia vaccines. Eurocine Vaccines AB (publ) was incorporated in 1999 and is based in Solna, Sweden.
Stock data | 2023 | Change |
---|---|---|
Price | $0.051951560864353846 | N/A |
Market Cap | $4.32M | N/A |
Shares Outstanding | 83.07M | 68.24% |
Employees | 3.00 | N/A |
Shareholder Equity | 3.21M | -79.39% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.22 | N/A |
P/B Ratio | 1.34 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.5151 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $0 | N/A |
Earnings | -$1.65M | N/A |
EPS | -0.2333 | N/A |
Earnings Yield | -4.49 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $502.31K | N/A |
Cash on Hand | $93.99K | N/A |
Debt to Equity | 0.0664 | 256.95% |
Current Ratio | $2.36 | -59.69% |